Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 73

Cited In for PubMed (Select 16839203)

1.

In Silico Docking to Explicate Interface between Plant-Originated Inhibitors and E6 Oncogenic Protein of Highly Threatening Human Papillomavirus 18.

Kumar S, Jena L, Sahoo M, Kakde M, Daf S, Varma AK.

Genomics Inform. 2015 Jun;13(2):60-7. doi: 10.5808/GI.2015.13.2.60. Epub 2015 Jun 30.

2.

The Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine Model.

Morokutti-Kurz M, König-Schuster M, Koller C, Graf C, Graf P, Kirchoff N, Reutterer B, Seifert JM, Unger H, Grassauer A, Prieschl-Grassauer E, Nakowitsch S.

PLoS One. 2015 Jun 8;10(6):e0128794. doi: 10.1371/journal.pone.0128794. eCollection 2015.

3.

λ-Carrageenan Suppresses Tomato Chlorotic Dwarf Viroid (TCDVd) Replication and Symptom Expression in Tomatoes.

Sangha JS, Kandasamy S, Khan W, Bahia NS, Singh RP, Critchley AT, Prithiviraj B.

Mar Drugs. 2015 May 8;13(5):2875-89. doi: 10.3390/md13052875.

4.

Marine polysaccharides from algae with potential biomedical applications.

de Jesus Raposo MF, de Morais AM, de Morais RM.

Mar Drugs. 2015 May 15;13(5):2967-3028. doi: 10.3390/md13052967. Review.

5.

Specific Inhibitory Effect of κ-Carrageenan Polysaccharide on Swine Pandemic 2009 H1N1 Influenza Virus.

Shao Q, Guo Q, Xu Wp, Li Z, Zhao Tt.

PLoS One. 2015 May 13;10(5):e0126577. doi: 10.1371/journal.pone.0126577. eCollection 2015.

6.

Peptidic inhibitors for in vitro pentamer formation of human papillomavirus capsid protein l1.

Fu DY, Jin S, Zheng DD, Zha X, Wu Y.

ACS Med Chem Lett. 2015 Feb 25;6(4):381-5. doi: 10.1021/ml500392y. eCollection 2015 Apr 9.

PMID:
25893037
7.

Non-clinical safety evaluation of intranasal iota-carrageenan.

Hebar A, Koller C, Seifert JM, Chabicovsky M, Bodenteich A, Bernkop-Schnürch A, Grassauer A, Prieschl-Grassauer E.

PLoS One. 2015 Apr 13;10(4):e0122911. doi: 10.1371/journal.pone.0122911. eCollection 2015.

8.

The HPV16 and MusPV1 papillomaviruses initially interact with distinct host components on the basement membrane.

Day PM, Thompson CD, Lowy DR, Schiller JT.

Virology. 2015 Jul;481:79-94. doi: 10.1016/j.virol.2015.02.021. Epub 2015 Mar 12.

PMID:
25771496
9.

Multipurpose prevention technologies: the future of HIV and STI protection.

Fernández-Romero JA, Deal C, Herold BC, Schiller J, Patton D, Zydowsky T, Romano J, Petro CD, Narasimhan M.

Trends Microbiol. 2015 Jul;23(7):429-36. doi: 10.1016/j.tim.2015.02.006. Epub 2015 Mar 7. Review.

10.

Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials.

Koenighofer M, Lion T, Bodenteich A, Prieschl-Grassauer E, Grassauer A, Unger H, Mueller CA, Fazekas T.

Multidiscip Respir Med. 2014 Nov 12;9(1):57. doi: 10.1186/2049-6958-9-57. eCollection 2014.

11.

Alginate hydrogel protects encapsulated hepatic HuH-7 cells against hepatitis C virus and other viral infections.

Tran NM, Dufresne M, Helle F, Hoffmann TW, François C, Brochot E, Paullier P, Legallais C, Duverlie G, Castelain S.

PLoS One. 2014 Oct 13;9(10):e109969. doi: 10.1371/journal.pone.0109969. eCollection 2014.

12.

Firmness Perception Influences Women's Preferences for Vaginal Suppositories.

Zaveri T, Primrose RJ, Surapaneni L, Ziegler GR, Hayes JE.

Pharmaceutics. 2014 Sep 10;6(3):512-29. doi: 10.3390/pharmaceutics6030512.

13.

Elucidating Molecular Interactions of Natural Inhibitors with HPV-16 E6 Oncoprotein through Docking Analysis.

Kumar S, Jena L, Galande S, Daf S, Mohod K, Varma AK.

Genomics Inform. 2014 Jun;12(2):64-70. doi: 10.5808/GI.2014.12.2.64. Epub 2014 Jun 30.

14.

Release of tenofovir from carrageenan-based vaginal suppositories.

Zaveri T, Hayes JE, Ziegler GR.

Pharmaceutics. 2014 Jul 4;6(3):366-77. doi: 10.3390/pharmaceutics6030366.

15.

In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition.

Rodríguez A, Kleinbeck K, Mizenina O, Kizima L, Levendosky K, Jean-Pierre N, Villegas G, Ford BE, Cooney ML, Teleshova N, Robbiani M, Herold BC, Zydowsky T, Fernández Romero JA.

Antiviral Res. 2014 Aug;108:88-93. doi: 10.1016/j.antiviral.2014.05.018. Epub 2014 Jun 5.

16.

Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.

Kwak K, Jiang R, Wang JW, Jagu S, Kirnbauer R, Roden RB.

PLoS One. 2014 May 9;9(5):e97232. doi: 10.1371/journal.pone.0097232. eCollection 2014.

17.

A potent combination microbicide that targets SHIV-RT, HSV-2 and HPV.

Kizima L, Rodríguez A, Kenney J, Derby N, Mizenina O, Menon R, Seidor S, Zhang S, Levendosky K, Jean-Pierre N, Pugach P, Villegas G, Ford BE, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Paglini G, Teleshova N, Zydowsky TM, Robbiani M, Fernández-Romero JA.

PLoS One. 2014 Apr 16;9(4):e94547. doi: 10.1371/journal.pone.0094547. eCollection 2014.

18.

Potential anti-HPV and related cancer agents from marine resources: an overview.

Wang SX, Zhang XS, Guan HS, Wang W.

Mar Drugs. 2014 Apr 3;12(4):2019-35. doi: 10.3390/md12042019. Review.

19.

Inhibition by cellular vacuolar ATPase impairs human papillomavirus uncoating and infection.

Müller KH, Spoden GA, Scheffer KD, Brunnhöfer R, De Brabander JK, Maier ME, Florin L, Muller CP.

Antimicrob Agents Chemother. 2014 May;58(5):2905-11. doi: 10.1128/AAC.02284-13. Epub 2014 Mar 10.

20.

Concepts of papillomavirus entry into host cells.

Day PM, Schelhaas M.

Curr Opin Virol. 2014 Feb;4:24-31. doi: 10.1016/j.coviro.2013.11.002. Epub 2013 Dec 14. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk